Kyverna Therapeutics, Inc. (KYTX) · Sep 24, 2026 · Other events

Kyverna’s CAR-T data clears the durability bar, but tiny gMG cohort remains

Above the bar — 95% sustained meaningful SPS benefit; 100% of seven gMG patients improved at 24 weeks

Kyverna shows durable one-year SPS benefit and longer-term gMG responses, strengthening its BLA case while leaving pivotal gMG proof ahead.

Kyverna is a late-stage clinical immunology company trying to move miv-cel from promising autoimmune CAR-T data toward an SPS approval while running a pivotal gMG trial. The broad direction was already established: the company had initiated the rolling SPS BLA, expected these longer-term data in the third quarter, and guided to gMG Phase 3 enrollment completion in mid-2027.

SPS durability is the clearest upgrade. In the 26-patient registrational trial, the key walking improvement did not fade at one year: median T25FW improvement was 49% at month 12 versus 46% at week 16, and 95% of patients who achieved a clinically meaningful response sustained it. 〔0〕 That is more than a repeat of the initial endpoint win; it directly supports Kyverna’s central commercial and regulatory argument that one infusion may replace chronic disease management. The fact that 92% remained free of chronic SPS immunotherapies adds practical weight. 〔1〕

The safety profile remains unusually clean for a CAR-T program, but this is confirmation rather than a new surprise. No high-grade CRS, ICANS, or IEC-HS appeared through the one-year follow-up. 〔2〕 That matters because tolerability is central to making an autologous CAR-T treatment viable in autoimmune disease, but Kyverna had already emphasized the same safety pattern across more than 100 treated patients in its recent pre-filing update.

gMG data are directionally strong but still preliminary. All seven Phase 2 patients achieved clinically meaningful MG-ADL and QMG improvement at 24 weeks, while follow-up now reaches one year or longer in five patients. 〔3〕 Six of seven remained off immunosuppressants at last follow-up, and 57% maintained minimal symptom expression. Those results reinforce the earlier positive signal, but the sample is too small and single-arm to establish comparative efficacy; the roughly 60-patient randomized Phase 3 trial remains the real validation step. The company still expects that enrollment to finish in mid-2027. 〔4〕

Bottom line: This is a meaningful de-risking update, especially for the SPS BLA: benefit persists, patients remain off chronic therapy, and no new safety problem emerges. It strengthens the approval story, while gMG remains a promising but still small-cohort thesis awaiting randomized Phase 3 confirmation.

What to watch next

SPS rolling BLA completion, Q4 2026

Original filing on SEC EDGAR

More Kyverna Therapeutics, Inc. news

Kyverna’s CAR-T data clears the durability bar, but tiny gMG cohort remains | KYTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.